NEYROS
The research company, carrying out studies and development of new pharmaceutical drug candidate for treatment of neurodegenerative disorders and cerebrovascular ischemia.
NEYROS projects are aimed at creating new pharmaceutical candidates for the treatment of Parkinson's disease, age-related dementia, Alzheimer's disease, as well as anti-ischemic drugs for increasing the duration of the "golden hour" during stroke.
Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work equally well for everyone. By mapping patients’ brain signals before and after taking the drug, they discovered that it sometimes activates the wrong brain regions, dampening its helpful effects. This breakthrough could pave the way for personalized treatment strategies, ensuring patients receive medications that target the right areas of their brain more effectively.
Motor function was improved in experimental models, paving the way for further research in humans.
A decade-long quest revealed that a mis-folded SOD1 protein drives Parkinson’s. Re-balancing its copper chemistry in mice erased tremor-like symptoms, opening the door to human trials. Credit: Shutterstock
Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson's disease and a way to modify it, paving the way for future treatments for the disease.
